Results 141 to 150 of about 16,591 (206)

Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception. [PDF]

BMC Cancer
Oliva M, Boitano M, Carbone A, Briata IM, Webber TB, Corradengo D, Introini C, Puntoni M, Ennas M, Germinale F, Provinciali N, Clavarezza M, Gozza A, Defferrari C, D'Amico M, Parnes HL, DeCensi A.   +16 more
europepmc   +1 more source

The Role of Nuclear Medicine in Prostate Cancer. [PDF]

Diagnostics (Basel)
Grozdic Milojevic I, Milojevic B, Skrijelj D, Bumbasirevic U, Janicic A, Kajmakovic B, Sobic-Saranovic D, Artiko V, Beatovic S.   +8 more
europepmc   +1 more source

Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy. [PDF]

EMBO Mol Med
Baurès M, Vieira Aleixo AS, Pacreau E, Koshy A, Friedrich V, Diedisheim M, Raigel M, Hua Y, Dariane C, Boutillon F, Kenner L, Marine JC, Laverny G, Metzger D, Rambow F, Guidotti JE, Goffin V.   +16 more
europepmc   +1 more source

Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia. [PDF]

BMC Urol
Bazarbashi S, Abdelmotal AS, Arabi T, Fallatah W, Alzannan N, Elhassan T, Aseafan M, Mahroos M, Aljishi M, Busbaih A, Aldandan R, Rauf MS, Almugbel FA, Azam F, Almansour M.   +14 more
europepmc   +1 more source

MCV/Q, Medical College of Virginia Quarterly, Vol. 14 No. 2 [PDF]

, 1978

core   +1 more source

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. [PDF]

Proc Natl Acad Sci U S A
Traphagen NA, Wheeler E, Li R, Akhshi T, Ravindranathan R, Alfieri C, Lu F, Ahmed B, Tewari AK, Balk SP, Nelson PS, Corey E, Long H, D'Andrea AD, Qiu X, Brown M.   +15 more
europepmc   +1 more source

Curative Lung Metastasectomy Without Concomitant Androgen Deprivation Therapy in Oligometastatic Castration-resistant Prostate Cancer: A Case Report and Review of the Literature [PDF]

, 2019
De Marchi, L, Gennari, A, Giavarra, M, Mosca, A Mantica G, Perrone, V, Terrone, C, Toncini, C   +6 more
core   +1 more source

PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape. [PDF]

Cancer Med
Chen Y, Cao J, Huang R, Lou J, Gu J, Luo Z, Yao T, Xie J.   +7 more
europepmc   +1 more source

The androgen receptor plays a suppressive role in epithelial- mesenchymal transition of human prostate cancer stem progenitor cells [PDF]

, 2015
Hao Bin, Ma Zhifang, Tu Rui, Wei Liang, Wu Nan, Zhang Shuhai, Zhang Wei   +6 more
core   +1 more source

Severe exfoliative dermatitis induced by apalutamide in a mHSPC patient: A case report. [PDF]

Medicine (Baltimore)
Chen H, Li T, Fan J, Liu J.
europepmc   +1 more source